October 29, 2019 U.S. Senator Martha McSally Visits C-Path U.S. Senator Martha McSally (Arizona) visited Tucson-based Critical Path Institute (C-Path) Friday, October 25, to learn more abou
October 22, 2019 Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data
October 21, 2019 Towards EMA Qualification of Islet Auto-Antibodies as a Model-Based Clinical Trial Enrichment Platform for Type-1 Diabetes Prevention Studies
October 15, 2019 C-Path, CDISC Develop Standard to Represent Data for Animal Rule Studies TUCSON, Ariz. and AUSTIN, Texas, October 15, 2019 — The Critical Path Institute (C-Path) and CDISC are pleased to announc
October 9, 2019 On September 25th, the FDA published a Personal Viewpoint in the American Journal of Transplantation
September 30, 2019 The Critical Path for Parkinson’s Consortium (CPP) welcomes PMD Alliance as newest member The Critical Path for Parkinson’s Consortium (CPP) is thrilled to welcome the PMD Alliance (Parkinson & Movement Disorder Al
September 25, 2019 Assessment of Long-term Neurodevelopmental Outcome Following Trials of Medicinal Products in Newborn Infants
September 23, 2019 Development of a Neonatal Adverse Event Severity Scale Through a Delphi Consensus Approach
September 23, 2019 Enabling efficient use of digital health technologies to support Parkinson’s disease drug development through precompetitive collaboration
September 20, 2019 The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T...